Drug Trial Radar · NCT04968574
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Last checked: Nov 19, 2026Latest source record: Dec 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41
Actual
Start
Aug 26, 2021
Primary completion
Nov 30, 2023
Study completion Nov 30, 2023
Sponsor
- Lead sponsor
- Endeavor Biomedicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of treatment. Following treatment, subjects will be observed for an additional 6 weeks.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
taladegibDrug
hedgehog pathway inhibitor dosed once daily
placeboDrug
identical tablets to the experimental arm with no active ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in frequency of adverse events (AEs)Time frame: Baseline to Week 18
- Change from baseline in severity of AEsTime frame: Baseline to Week 18
- Change from baseline in vital sign measurements - pulseTime frame: Baseline to Week 18
- Change from baseline in vital sign measurements - blood pressureTime frame: Baseline to Week 18
- Change from baseline in vital sign measurements - respiration rateTime frame: Baseline to Week 18
- Change from baseline in vital sign measurements - temperatureTime frame: Baseline to Week 18
- Change from baseline in blood oxygen saturation levelTime frame: Baseline to Week 18
- Incidence of clinical laboratory abnormalitiesTime frame: Baseline to Week 18
- Severity of clinical laboratory abnormalitiesTime frame: Baseline to Week 18
- Number of hospitalizationsTime frame: Baseline to Week 18
Locations
24 sites in 5 countries. Site status is shown where the registry gives one.
Research Site
Liverpool, New South Wales, Australia
Research Site
Benowa, Queensland, Australia
Research Site
Box Hill, Victoria, Australia
Research Site
Clayton, Victoria, Australia
Research Site
Vancouver, British Columbia, Canada
Research Site
Sherbrooke, Quebec, Canada
Research Site
Batu Caves, Malaysia
Research Site
Kota Bharu, Malaysia
Research Site
Kuala Lumpur, Malaysia
Research Sire
Kuala Lumpur, Malaysia
Research Site
Kuala Lumpur, Malaysia
Research Site
Chihuahua City, Mexico
Research Site
Mexico City, Mexico
Research Site
Mexico City, Mexico
Research Site
Oaxaca City, Mexico
Research Site
Puebla City, Mexico
Research Site
Monterrey, Nuevo León, Mexico
Research Site
Monterrey, Nuevo León, Mexico
Research Site
San Nicolás de los Garza, Nuevo León, Mexico
Research Site (Namdong District)
Incheon, South Korea
Research Site (Bundang District)
Seongnam, South Korea
Research Site (Gangnam District)
Seoul, South Korea
Research Site (Seongbuk District)
Seoul, South Korea
Research Site (Songpa District)
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.